{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:58:03Z","timestamp":1768687083795,"version":"3.49.0"},"reference-count":25,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":165,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Perampanel is a selective, noncompetitive amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor antagonist indicated for management of partial-onset and primary generalized seizures in epilepsy patients aged \u226512 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patient History<\/jats:title>\n                  <jats:p>A 29-year-old, white female with significant history of medically refractory frontal lobe epilepsy, status post right frontal and temporal resections, was initiated on perampanel as an add-on therapy to phenytoin extended-release (330 mg\/d) and clonazepam (2.5 mg\/d). She previously failed several antiepileptic drugs because of inefficacy and\/or intolerance. Perampanel was initiated at 2 mg\/d and the dose was increased by 2 mg\/d increments every 2 to 3 weeks. Following the first dose, nausea and drowsiness were reported but resolved the following day. Three days after titration to 6 mg\/d, the patient developed complete food aversion and became more irritable and anxious while no seizure frequency improvement was noted. No change of sense of taste was reported. After reduction to 4 mg\/d, adverse effects improved but did not completely resolve until 2 months following perampanel discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Review of Literature<\/jats:title>\n                  <jats:p>A PubMed search revealed no published literature or case reports of perampanel-induced food aversion or anorexia in a presence or absence of phenytoin and clonazepam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this report, a temporal relationship was observed between perampanel dose-increase and the development of food aversion. Return to baseline appetite and eating habits following perampanel discontinuation strongly suggest perampanel involvement. At this time, the exact mechanism(s) behind food aversion associated with perampanel is\/are unknown.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2019.03.100","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T17:45:55Z","timestamp":1551462355000},"page":"100-104","source":"Crossref","is-referenced-by-count":2,"title":["Perampanel-induced, new-onset food aversion in a 29-year-old female with medically refractory frontal lobe epilepsy"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-8921","authenticated-orcid":false,"given":"Marketa","family":"Marvanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"key":"2022042505184234500_i2168-9709-9-2-100-b01","article-title":"FYCOMPA (perampanel) tablets, package insert [Internet]","author":"Eisai Inc","year":"2018"},{"issue":"Suppl 1","key":"2022042505184234500_i2168-9709-9-2-100-b02","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/epi.12495","article-title":"Introduction: Perampanel--new mode of action and new option for patients with epilepsy","volume":"55","author":"Steinhoff","year":"2014","journal-title":"Epilepsia"},{"issue":"11","key":"2022042505184234500_i2168-9709-9-2-100-b03","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"2022042505184234500_i2168-9709-9-2-100-b04","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"2022042505184234500_i2168-9709-9-2-100-b05","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"2022042505184234500_i2168-9709-9-2-100-b06","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"2022042505184234500_i2168-9709-9-2-100-b07","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"issue":"Suppl","key":"2022042505184234500_i2168-9709-9-2-100-b08","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jns.2017.08.961","article-title":"Perampanel as an adjunctive therapy in patients with frontal lobe epilepsy in Taiwan","volume":"381","author":"Cheng","year":"2017","journal-title":"J Neurol Sci [Internet]"},{"key":"2022042505184234500_i2168-9709-9-2-100-b09","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res"},{"issue":"3","key":"2022042505184234500_i2168-9709-9-2-100-b10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3988\/jcn.2018.14.3.296","article-title":"Adverse events during perampanel adjunctive therapy in intractable epilepsy","volume":"14","author":"Youn","year":"2018","journal-title":"J Clin Neurol"},{"key":"2022042505184234500_i2168-9709-9-2-100-b11","doi-asserted-by":"crossref","unstructured":"Logue\n              AW\n            . \n          The psychology of eating and drinking. 4th ed. New York and London: Routledge;2015.","DOI":"10.4324\/9780203387924"},{"issue":"3","key":"2022042505184234500_i2168-9709-9-2-100-b12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0195-6663(92)90164-2","article-title":"Taste and food preference changes across the course of pregnancy","volume":"19","author":"Bowen","year":"1992","journal-title":"Appetite"},{"key":"2022042505184234500_i2168-9709-9-2-100-b13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1749-6632.1985.tb27082.x","article-title":"Conditioned food aversion learning in humans","volume":"443","author":"Logue","year":"1985","journal-title":"Ann N Y Acad Sci"},{"key":"2022042505184234500_i2168-9709-9-2-100-b14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"1","key":"2022042505184234500_i2168-9709-9-2-100-b15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"2022042505184234500_i2168-9709-9-2-100-b16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuroscience.2016.07.010","article-title":"GABA levels in the ventromedial prefrontal cortex during the viewing of appetitive and disgusting food images","volume":"333","author":"Padulo","year":"2016","journal-title":"Neuroscience"},{"issue":"2","key":"2022042505184234500_i2168-9709-9-2-100-b17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1523\/JNEUROSCI.1202-15.2016","article-title":"Lateral hypothalamic area glutamatergic neurons and their projections to the lateral habenula regulate feeding and reward","volume":"36","author":"Stamatakis","year":"2016","journal-title":"J Neurosci"},{"issue":"5","key":"2022042505184234500_i2168-9709-9-2-100-b18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg-Martin","year":"2010","journal-title":"Neuron"},{"issue":"1-2","key":"2022042505184234500_i2168-9709-9-2-100-b19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0006-8993(00)02397-0","article-title":"Different disruptive effects on the acquisition and expression of conditioned taste aversion by blockades of amygdalar ionotropic and metabotropic glutamatergic receptor subtypes in rats","volume":"869","author":"Yasoshima","year":"2000","journal-title":"Brain Res"},{"key":"2022042505184234500_i2168-9709-9-2-100-b20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.brainres.2010.05.008","article-title":"Stimulation of lateral hypothalamic AMPA receptors may induce feeding in rats","volume":"1346","author":"Hettes","year":"2010","journal-title":"Brain Res"},{"issue":"1-2","key":"2022042505184234500_i2168-9709-9-2-100-b21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0006-8993(01)03094-3","article-title":"Excitatory amino acid receptor subtype agonists induce feeding in the nucleus accumbens shell in rats: opioid antagonist actions and interactions with \u03bc-opioid agonists","volume":"921","author":"Echo","year":"2001","journal-title":"Brain Res"},{"issue":"1-2","key":"2022042505184234500_i2168-9709-9-2-100-b22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0166-4328(97)00140-X","article-title":"Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell","volume":"93","author":"Stratford","year":"1998","journal-title":"Behav Brain Res"},{"issue":"6","key":"2022042505184234500_i2168-9709-9-2-100-b23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bj.2017.09.003","article-title":"Preliminary Asian experience of using perampanel in clinical practice","volume":"40","author":"Chiang","year":"2017","journal-title":"Biomed J"},{"issue":"8","key":"2022042505184234500_i2168-9709-9-2-100-b24","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"issue":"2","key":"2022042505184234500_i2168-9709-9-2-100-b25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bcp.12951","article-title":"Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials","volume":"82","author":"Majid","year":"2016","journal-title":"Br J Clin Pharmacol"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/2\/100\/2427804\/mhc_2019_03_100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/2\/100\/2427804\/mhc_2019_03_100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:50Z","timestamp":1731687770000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/2\/article-p100.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.03.100","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}